ReviewTherapeutic innovation & regulatory science2026
Viral Clearance: Safety and Efficiency of Biopharmaceuticals.
Review in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral clearance is a vital procedure in the pharma industry, safeguarding the well-being of drug products by eradicating or inactivating possible viral toxins while manufacturing. This includes a multifaceted method, along with laborious testing of raw materials, process design, optimization, and validation studies to demonstrate the effectiveness of viral clearance steps. Nowadays, this topic has become more challenging and versatile with the development of new viruses in the environment. This manuscript focuses on the potential routes of viral contamination, including viral impurities present in the master cell bank, and contaminated virus introduced during manufacturing, adventitious viruses from raw materials, principles of viral clearance, regulatory framework, design of viral clearance studies interpretation and limitations, emerging technologies and trends, viral clearance strategies such as inactivation methods: low pH, solvent/detergent, heat treatment and removal methods like chromatography, nanofiltration, precipitation and related case studies.
Indexed as
Identifiers
41678029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.